Optimizing Guideline-directed Medical Therapies for Heart Failure with Reduced Ejection Fraction During Hospitalization
暂无分享,去创建一个
[1] D. DeMets,et al. Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.
[2] Andrew J. Sauer,et al. Practical guidance on the use of sacubitril/valsartan for heart failure , 2018, Heart Failure Reviews.
[3] C. Tsioufis,et al. Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis , 2018, Heart Failure Reviews.
[4] Akshay S. Desai,et al. Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial , 2016, Circulation. Heart failure.
[5] I. Piña,et al. Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association , 2013, Circulation. Heart failure.
[6] Akshay S. Desai,et al. Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM‐HF trial , 2016, European journal of heart failure.
[7] P. Ponikowski,et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial , 2020, The Lancet.
[8] E. Braunwald,et al. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. , 2019, JAMA cardiology.
[9] M. Piepoli,et al. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH) , 2004, BMJ : British Medical Journal.
[10] R. Doughty,et al. Renal Dysfunction in Heart Failure Patients with Preserved versus Reduced Ejection Fraction: Impact of the New CKD-EPI Formula , 2012 .
[11] Akshay S. Desai,et al. Initiation, Continuation, or Withdrawal of Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction , 2017, Journal of the American Heart Association.
[12] B. Agrawal,et al. Comparison of the antihypertensive effects of carvedilol and metoprolol on resting and exercise blood pressure , 2004, The clinical investigator.
[13] K. Sidhu,et al. Hyperkalemia in heart failure , 2019, Current opinion in cardiology.
[14] CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial , 1999, The Lancet.
[15] C. Morgan,et al. Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure. , 2015, The American journal of medicine.
[16] X. Qian,et al. Liberal versus restricted fluid administration in heart failure patients. A systematic review and meta-analysis of randomized trials. , 2015, International heart journal.
[17] S. Solomon,et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials , 2020, The Lancet.
[18] J. Butler,et al. Timely Management of New-Onset Heart Failure. , 2019, Circulation.
[19] G. Ogedegbe,et al. Heart failure–associated hospitalizations in the United States. , 2013, Journal of the American College of Cardiology.
[20] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[21] J. Butler,et al. Correction to: Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. , 2021, Circulation.
[22] F. Tristani,et al. Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure , 1986 .
[23] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[24] P. Austin,et al. Associations Between Short or Long Length of Stay and 30-Day Readmission and Mortality in Hospitalized Patients With Heart Failure. , 2017, JACC. Heart failure.
[25] S. Gottlieb,et al. Observation of Patients Transitioned to an Oral Loop Diuretic Before Discharge and Risk of Readmission for Acute Decompensated Heart Failure. , 2017, Journal of cardiac failure.
[26] B. Zinman,et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.
[27] A. Nabhan,et al. Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review. , 2015, International journal of cardiology.
[28] Wing W. Chan,et al. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. , 2016, JAMA cardiology.
[29] H. Heerspink,et al. Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐AHF) , 2020, European journal of heart failure.
[30] M. Guglin,et al. Post-discharge rise in BNP and rehospitalization for heart failure , 2019, Herz.
[31] P. Ponikowski,et al. Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT‐CHF , 2017, European journal of heart failure.
[32] C. O'connor,et al. Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. , 2007, Journal of cardiac failure.
[33] S. Duval,et al. Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis. , 2015, JACC. Heart failure.
[34] Jane A. Linderbaum,et al. 2013 ACCF/AHA Guideline for the Management of ST‐Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[35] L. Tomlinson,et al. Change in renal function associated with drug treatment in heart failure: national guidance , 2019, Heart.
[36] Deepak L. Bhatt,et al. Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling. , 2018, Journal of the American College of Cardiology.
[37] Janna C. Beavers,et al. Risk Factors for Intolerance of Inpatient Sacubitril/Valsartan Initiation , 2019, Journal of pharmacy practice.
[38] G. D. Di Tanna,et al. A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014–2020) , 2020, PharmacoEconomics.
[39] D. Conen,et al. Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial. , 2019, JAMA.
[40] Christopher L. Roy,et al. 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2019, Journal of the American College of Cardiology.
[41] G. Fonarow,et al. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. , 2018, Journal of the American College of Cardiology.
[42] V. Hasselblad,et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. , 2004, Journal of the American College of Cardiology.
[43] J. McMurray,et al. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[44] J. Skinner,et al. Use of Guideline-Directed Medications for Heart Failure Before Cardioverter-Defibrillator Implantation. , 2016, Journal of the American College of Cardiology.
[45] N. Hara,et al. Effect of Optimizing Guideline-Directed Medical Therapy Before Discharge on Mortality and Heart Failure Readmission in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. , 2018, The American journal of cardiology.
[46] F. Coppi,et al. Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure , 2015, Journal of the renin-angiotensin-aldosterone system : JRAAS.
[47] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[48] I. Piña,et al. Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance , 2017, ESC heart failure.
[49] Deepak L. Bhatt,et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.
[50] M. Vaduganathan,et al. Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure. , 2020, Circulation. Heart failure.
[51] J. Rouleau,et al. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. , 2004, Journal of the American College of Cardiology.
[52] R. Wenzel. Diuretics in heart failure. , 1986, Lancet.
[53] M. Khan,et al. Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis , 2017, Circulation. Heart failure.
[54] R. Doughty,et al. Renal Dysfunction in Patients With Heart Failure With Preserved Versus Reduced Ejection Fraction: Impact of the New Chronic Kidney Disease-Epidemiology Collaboration Group Formula , 2012, Circulation. Heart failure.
[55] F. McAlister,et al. Trends in Readmissions and Length of Stay for Patients Hospitalized With Heart Failure in Canada and the United States. , 2019, JAMA cardiology.
[56] Neha J. Pagidipati,et al. Barriers to prescribing glucose-lowering therapies with cardiometabolic benefits. , 2020, American heart journal.
[57] M. Mrkobrada,et al. Mineralocorticoid receptor antagonists for heart failure: systematic review and meta-analysis , 2016, BMC Cardiovascular Disorders.
[58] V. Roger,et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.
[59] D. Atar,et al. Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study , 2015, Circulation. Heart failure.
[60] Deepak L. Bhatt,et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. , 2020, The New England journal of medicine.
[61] D. DeMets,et al. Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF , 2020, European Heart Journal.
[62] W. Kraus,et al. Relationship of beta-blocker dose with outcomes in ambulatory heart failure patients with systolic dysfunction: results from the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial. , 2012, Journal of the American College of Cardiology.
[63] Biykem Bozkurt,et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.
[64] P. Ponikowski,et al. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. , 2021, JAMA cardiology.
[65] C. Morgan,et al. DISCHARGE INITIATION OF ACE INHIBITORS OR ARBS IS ASSOCIATED WITH SIGNIFICANTLY LOWER 30-DAY ALL-CAUSE READMISSION IN HOSPITALIZED OLDER PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION , 2014 .
[66] G. Filippatos,et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials , 2020, The Lancet.
[67] V. Hasselblad,et al. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). , 2016, The American journal of cardiology.
[68] J. McMurray,et al. Renin–Angiotensin System Inhibition, Worsening Renal Function, and Outcome in Heart Failure Patients With Reduced and Preserved Ejection Fraction: A Meta-Analysis of Published Study Data , 2017, Circulation. Heart failure.
[69] Eiran Z. Gorodeski,et al. Telehealth for Uptitration of Guideline-Directed Medical Therapy in Heart Failure. , 2020, Circulation.
[70] I. Piña,et al. Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. , 2016, JACC. Heart failure.
[71] S Hood,et al. Clinical service organisation for heart failure. , 2005, The Cochrane database of systematic reviews.
[72] E. Braunwald,et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure , 2019, The New England journal of medicine.
[73] K. Anstrom,et al. A reappraisal of loop diuretic choice in heart failure patients. , 2015, American heart journal.
[74] S. Blecker,et al. Mineralocorticoid receptor antagonist use after hospitalization of patients with heart failure and post-discharge outcomes: a single-center retrospective cohort study , 2019, BMC Cardiovascular Disorders.
[75] J. H. Patterson,et al. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. , 2018, Journal of the American College of Cardiology.
[76] A. Al-Mohammad. Hydralazine and nitrates in the treatment of heart failure with reduced ejection fraction , 2019, ESC heart failure.
[77] S. Goldsmith,et al. Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure. , 2019, The American journal of cardiology.
[78] Rapid carvedilol up-titration in hospitalized patients with systolic heart failure. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[79] A. Hungin,et al. Barriers to accurate diagnosis and effective management of heart failure have not changed in the past 10 years: a qualitative study and national survey , 2014, BMJ Open.
[80] N. Honarpour,et al. Real‐World Analysis of Guideline‐Based Therapy After Hospitalization for Heart Failure , 2020, Journal of the American Heart Association.
[81] Akshay S. Desai,et al. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial , 2017, JAMA cardiology.
[82] E. Ellerbeck,et al. Patients' annual income adequacy, insurance premiums and out-of-pocket expenses related to heart failure care. , 2014, Heart & lung : the journal of critical care.
[83] S. Solomon,et al. Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. , 2020, JAMA cardiology.